NewAmsterdam Pharma (NAMS) Stock Overview
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NAMS Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.75 |
| 52 Week High | US$42.21 |
| 52 Week Low | US$16.79 |
| Beta | 0.028 |
| 1 Month Change | 5.71% |
| 3 Month Change | 3.23% |
| 1 Year Change | 93.14% |
| 3 Year Change | 179.41% |
| 5 Year Change | 265.54% |
| Change since IPO | 231.02% |
Recent News & Updates
Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts
Celebrations may be in order for NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) shareholders, with the analysts...NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
Summary NewAmsterdam Pharma is advancing obicetrapib, an oral CETP inhibitor, targeting unmet LDL-C lowering needs in cardiovascular disease patients. Obicetrapib met primary and secondary endpoints in three Phase 3 trials, with significant LDL-C reductions and favorable safety, supporting regulatory filings in Europe and the US. NAMS anticipates regulatory decisions in Europe in H2 2026, with US NDA likely post-PREVAIL CVOT data; commercial preparations and partnerships are underway. With $729m cash and multiple ongoing studies, NAMS faces single-asset risk but holds significant upside from potential multi-indication approvals and European royalty streams. Read the full article on Seeking AlphaRecent updates
Shareholder Returns
| NAMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.3% | -3.0% | -0.3% |
| 1Y | 93.1% | 32.9% | 26.7% |
Return vs Industry: NAMS exceeded the US Biotechs industry which returned 28.1% over the past year.
Return vs Market: NAMS exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| NAMS volatility | |
|---|---|
| NAMS Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NAMS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NAMS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 100 | Michael Davidson | www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
| NAMS fundamental statistics | |
|---|---|
| Market cap | US$3.88b |
| Earnings (TTM) | -US$212.73m |
| Revenue (TTM) | US$22.57m |
Is NAMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAMS income statement (TTM) | |
|---|---|
| Revenue | US$22.57m |
| Cost of Revenue | US$0 |
| Gross Profit | US$22.57m |
| Other Expenses | US$235.30m |
| Earnings | -US$212.73m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -942.76% |
| Debt/Equity Ratio | 0% |
How did NAMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 22:24 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NewAmsterdam Pharma Company N.V. is covered by 19 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Geoffrey Meacham | Citigroup Inc |
| Asad Haider | Goldman Sachs |